Atlas Trials

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

Clinical trial NCT05458401 · COMPLETED

Trial details

NCT number
NCT05458401
Sponsor
Daiichi Sankyo
Status
COMPLETED
Study type
OBSERVATIONAL
HER2-positive Breast Cancer
Start date
2022-11-11
Primary completion
2023-12-01
Enrollment
256

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.